Replimune (REPL) Interest & Investment Income (2018 - 2026)
Replimune (REPL) reported Interest & Investment Income of $2.4 million for Q1 2026, down 59.69% on a YoY basis from $5.9 million in Q1 2025, and down 16.76% sequentially from $2.8 million in Q4 2025.
Replimune (REPL) Interest & Investment Income (2018 - 2026) Analysis & Trends
Replimune (REPL) has 9 years of Interest & Investment Income data on file, last reported at $2.4 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 59.69% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (down 35.48% YoY), and the FY2026 full-year result was $13.6 million, down 35.49% from the prior year.
- Interest & Investment Income fell to $2.4 million in Q1 2026, from $2.8 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $6.2 million in Q2 2023 to a low of $131000.0 in Q1 2022.
- A 5-year average of $4.0 million and a median of $4.7 million in 2025 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income jumped 4385.5% in 2023 and slumped 59.69% in 2026, its largest moves.
- Tracing REPL's Interest & Investment Income over 5 years: stood at $2.7 million in 2022, then surged by 112.56% to $5.7 million in 2023, then dropped by 9.66% to $5.1 million in 2024, then tumbled by 44.6% to $2.8 million in 2025, then declined by 16.76% to $2.4 million in 2026.
- Business Quant data shows REPL's Interest & Investment Income at $2.4 million in Q1 2026, $2.8 million in Q4 2025, and $3.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Replimune | 808.32 Mn | 808.32 Mn | - | 2.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 2.85 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 4.71 Mn |
| Mar 31, 2025 | 5.88 Mn |
| Dec 31, 2024 | 5.14 Mn |
| Sep 30, 2024 | 5.39 Mn |
| Jun 30, 2024 | 4.71 Mn |
| Mar 31, 2024 | 5.43 Mn |
| Dec 31, 2023 | 5.69 Mn |
| Sep 30, 2023 | 6.05 Mn |
| Jun 30, 2023 | 6.19 Mn |
| Mar 31, 2023 | 5.88 Mn |
| Dec 31, 2022 | 2.68 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | 343,000.00 |
| Mar 31, 2022 | 131,000.00 |
| Dec 31, 2021 | 87,000.00 |
| Sep 30, 2021 | 80,000.00 |
| Jun 30, 2021 | 92,000.00 |